Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18424508 | 0.91 | KMT2A (0.56) | JAK2JAK1AGTR2LTA4HOPRM1 | |
| SCHEMBL7280301 | 0.90 | LTA4H (0.63) | JAK2JAK1AGTR2LTA4HOPRM1 | |
| SCHEMBL29101926 | 0.87 | LTA4H (0.47) | JAK2JAK1AGTR2LTA4HOPRM1 | |
| SCHEMBL27544931 | 0.85 | CHIA (0.52) | AGTR2OPRM1SIGMAR1KMT2AGRIN2B | |
| SCHEMBL27577321 | 0.85 | ALDH1A1 (0.70) | JAK2JAK1SIGMAR1KMT2AKDM4E | |
| SCHEMBL144125 | 0.84 | KMT2A (0.51) | JAK2JAK1AGTR2OPRM1SIGMAR1 | |
| SCHEMBL26618018 | 0.84 | KMT2A (0.55) | JAK2JAK1AGTR2LTA4HOPRM1 | |
| SCHEMBL20160113 | 0.83 | ALDH1A1 (0.56) | JAK2JAK1AGTR2LTA4HOPRM1 | |
| SCHEMBL803527 | 0.83 | JAK2 (0.74) | JAK2JAK1KMT2AKDM4EMEN1 | |
| SCHEMBL16192363 | 0.83 | JAK2 (0.74) | JAK2JAK1AGTR2LTA4HOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105555778-A | Cyclic amine derivative and pharmaceutical use thereof | TORAY INDUSTRIES | 2016-05-04 | — | — | CN | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| EP-2619178-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2013-07-31 | — | — | EP | disclosed |
| CN-103097354-A | Substituted benzamide compounds | GRUENENTHAL CHEMIE | 2013-05-08 | — | — | CN | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| EP-2102171-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008071646-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | JAK2 1298/4885JAK1 1517/4885AGTR2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.